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AbstRACt
background: Data regarding burden of illness borne by women affected with cancer of the cervix (CaCvx) has been largely 
anecdotal. This study aimed to evaluate disability and cost burden of the illness in northern Nigeria.
Materials and Methods: Cost of illness was determined using the bottom‑up approach and involved estimating costs of 
managing various stages of the illness while disability adjusted life year (DALY) was estimated sing CaCvx survival data 
from northern Nigeria.
Results: Overall cost of illness ranged from ₦191,338 ($524) to ₦1,001,298 ($2,743) for local to metastatic 
diseases, respectively. Of these, direct medical costs accounted for up to 75.4% while indirect costs accounted 
for up to 48% in different stages of the disease. Productivity losses ranged from 18.3% to 43.1%, while surgical, 
medical, and radiotherapies accounted for losses between 37.2% and 46%. Estimated DALY was 269 years/100,000 
women with cost/DALY saved on treatment estimated at between $19 and $1,443 for different stages. At the 
discounted rate, it was estimated that it would be 16 to 902 times cheaper to screen for the disease than to treat 
(P < 0.0001).
Conclusion: Though burden of illness borne by women with CaCvx in northern Nigeria is similar to that borne by women 
in other developing countries, it is still too high; and the only panacea to this is institution of early screening programs and 
immunization. In addition, concerted effort is needed to ensure extension of health insurance coverage for cancer therapy 
and increase in availability of radiotherapy service as a means of reducing waiting times for treatment.
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Introduction
In Nigeria, cervical cancer is associated with age-standardized 
incidence and mortality rates of 36 per 100,000 and 
17.5 per 100,000, respectively, and younger mean age of 
occurrence (4th decade) among Nigerian women.[1-3] However, 
these data do not reflect the social and economic burden of 
the disease.
As a means of capturing the real cost of diseases, the 
Global Burden of Diseases (GBD) study introduced the 
concept of disability adjusted life year (DALY).[4] This sums 
up years of life lost due to disability (YLD) with years of 
life lost (YLL) due to premature death. The value of healthy 
life lost for different diseases (DALY saved/$) can then 
be compared and used as a guide for prioritizing health 
resource allocation.[5]
Thus, the aim of this study is to evaluate the burden of 
cervical cancer in Kano, northern Nigeria by computing DALY 
as well as the cost of illness for cervical cancer.
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Materials and Methods
In estimating the cost of illness for cervical cancer, the 
bottom-up approach was adopted and all values were 
rendered in Naira (and US dollar equivalent at average 2016 
rate of ₦365: 1 Dollar). Direct medical costs were based on 
costs of requisite investigations, drugs, consultation, and 
other services in a teaching hospital in northwestern Nigeria, 
being the hospital serving the largest population in the north. 
Direct medical costs included cost of obtaining a hospital card, 
consultation, microbiological, hematological, biochemical, 
histopathological, and radiological investigations, as well 
as medical and surgical procedures, examination under 
anesthesia, blood transfusion, and radiotherapy.
These costs were computed for worst case scenarios of 
Localized disease (1a1, 1a2, 1b1, 1b2, and 2a), regional 
disease (2b, 3a and 3b), and metastatic disease (4a and 4b). 
Salvage dialysis was computed as three sessions per week 
before nephrostomy.
Costs of transportation to and from the hospital (N1, 000; $2.7) 
was based on 2016 average cost from the furthest part of the 
state to the hospital. This also included the cost of transportation 
to a radiotherapy reference facility also in northern Nigeria.
Productivity losses were calculated at N102 ($0.3) per hour 
based on the minimum monthly wage of N18, 000 ($49.3) 
for 8-hour work days and 22 days a month. Due to the usual 
long waiting periods, productivity loss was estimated to be 
a full work day. Productivity loss of an accompanying relative 
was also calculated but only for the days on admission. 
Productivity losses were also only calculated for a year and 
did not include potential losses due to premature mortality.
In calculating disability adjusted life years (DALY), the formula:
DALY = Years of life lost due to disability (YLD) + Years of 
live lost (YLL) prematurely was used;[6] where:
YLD (at 3% discount rate) =0.6 (−0.03)−1 (e^ (−0.03t); and 
t = 2 years. The 2 years adopted in the calculation was based 
on the study by Musa et al.[7] in northern Nigeria who reported 
mean duration of 23.7 months survival among women with 
cervical cancer.
YLL (at 3% discount rate) was calculated using the formula: 
e^ (−0.03*t) (1 – e^ (−0.03L); where L = age at death).
Age discounting was calculated using the formula; 
0.1658(Xe^ 0.04X) where X is age.
Based on the study by Yakassai et al.,[8] with age range of 
35–74 years, the ages computed were 35, 45, 55, and 
75 years. Life expectancy for these ages were derived from life 
expectancy tables.[9] Disability weights assigned to cervical 
cancer with and without treatment were 0.540 and 0.569, 
respectively, as described in the GBD, 2013.[10]
Results
As shown in Table 1, the cost of treatment for localized 
to metastatic carcinoma of the cervix ranged from 
₦191,338 ($524) to ₦1,001,298 ($2,743), respectively. 
Estimated direct medical costs accounted for the bulk of 
calculated expenditure with medical and surgical procedures 
as well as medications accounting for between 37.2% and 
46.0% of costs. Cost of consultations and health records 
accounted for the least fraction (0.4–1.5%) of estimated 
expenditure. Productivity losses accounted for the bulk 
of estimated costs for regional and metastatic diseases at 
43.1% and 42.4% of costs, respectively. There was statistically 
significant difference in estimates of direct versus indirect 
costs for the three stratified stages with direct medical costs 
being the highest for early-stage tumors (Chi-square stat 
14.08; P = 0.0008).
The years of life lived with disability (YLD) was uniform across 
the selected ages and was 1.1 years out of the 2 years actually 
Table 1: Breakdown of costs of different stages of cervical cancer
Item estimated Localized tumor 1a, b and 
2a (₦, %)
Regional tumor
2b, 3a and 3b (₦, %)
Metastatic tumor 4a and b 
(₦, %)
Direct costs
Consultation + Records 2,900 1.5 3,700 0.4 6,400 0.6
Laboratory 35,350 18.5 88,850 9.0 99,050 9.9
Radiology 18,000 9.4 48,000 4.9 51,000 5.1
Procedures + Medications 88,000 46.0 372,000 37.7 372,000 37.2
Indirect costs
Transportation costs 12,000 6.3 48,000 4.9 48,000 4.8
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lived. Based on the remnant unlived life expectancy, years of 
life lost (YLL) due to premature death fell progressively from 
19.0 years for a woman who was diagnosed at 35 years and 
died at 37 years to 4.8 years for a woman diagnosed at the 
age of 75 who survived for 2 years after diagnosis [Table 2]. 
Age and time discounted DALY also fell progressively from 
28.0 years for a woman diagnosed at 35 years to 1.9 years 
for a woman diagnosed at 75 years.
Average YLL was estimated at 13.1 and age standardized rate 
of 229.3 years per 100,000 women aged 35 to 75 years. Age 
standardized YLD and DALY were estimated to be 39.6 years 
and 269 years per 100,000 women, respectively. Cost per 
DALY saved ranged from ₦6,834 ($19) to ₦100,704 ($276) 
for the treatment of localized tumor to ₦35,761 ($98) and 
₦526,999 ($1,443) for the treatment of metastatic tumor. 
There was also statistically significant difference in DALY 
relative to cost per DALY saved for early to metastatic stages 
of the disease (Chi‑square 247.7; P < 0.0001).
Discussion
Estimated cost of illness for cervical cancer in our study 
ranges from ₦191,338 (524 US$) to ₦1,001,298 ($2,743) 
for local to metastatic disease. Our estimated cost of 
treating localized tumor is lower than the range of $2,014 
in India to $6,496 estimated for South Africa, but similar 
to the $2,683 in Kenya and $2,933 in India for treatment 
of advanced disease. It is, however, lower than the $3,680 
in South Africa[11] [Table 3]. At our estimated rate, based on 
extrapolated annual growth rate of 2.6% from 2006 census 
figures,[12,13] 788 of 2,187,628 women (35–74 years of age) 
in Kano state would require an average of about $1,567,332 
for a year of treatment. This is higher than the total 
estimated cost of $1,429,673 required to treat 550 patients 
documented in a study from Morocco.[14] Nevertheless, 
these costs, similar to ours, show the significant economic 
burden borne by women with the disease, especially 
against the backdrop of a national per capital GDP of 
$2,178 (2016).[15]
In this analysis, direct medical costs accounted for up to 
75.4% while indirect costs accounted for up to 48%. Our 
estimated fractions are comparable to those reported 
from Ethiopia (74%: 26%; medical to non‑medical) but less 
than the 90%: 10% described in the US study.[16,17] While 
radiotherapy (including brachytherapy) accounted for 80% 
of costs in the Moroccan study, these only accounted for 
4% of our estimated costs. The higher value may be due to 
non‑inclusion of indirect costs in the Moroccan study. In 
contrast, productivity losses accounted for the bulk of costs 
in our study with values of up to 43.1%.
The Economist Intelligence Unit[18] derived a global economic 
cost of US$286 billion for new cancer cases in 2009, 24% of 
which resulted from productivity losses. Pearce et al.[19] in 
their study have projected that in Europe, over a period of 
19 years (2011–2030), productivity losses attributable to 
cervical cancer will amount to about €155,000 per death. 
Similarly, a woman in Nigeria, diagnosed and died of cervical 
cancer in 2016 at the age of 35 years, based on retirement age 
of 65 years, at 1% annual salary increment, 15% inflation rate, 
and exchange rate of ₦310.4:1€, stands a life time earning 
loss of approximately €67,470.
Such productivity loss, at the barest minimum wage utilized 
in this computation, may best be conceptualized in terms 
of household income loss, bringing to focus a part of the 
illness burden borne by the patient’s family. Household 
expenditure, as reported by Oguntayo and colleagues[20] in 
Zaria, northern Nigeria was estimated to be between $700 
and $2,050, with family and relatives footing the bill in as 
much as 57% of cases.






YLD YLL DALY§ Cost/DALY saved 
on treatment; ₦
($)
35 30.9 1.1 19.0 28.0 6,834-35,761 (19-98)
45 24.1 1.1 16.1 20.7 9,243-48,372 (25-133)
55 17.1 1.1 12.6 13.7 13,966-73,087 (38-200)
75 5.5 1.1 4.8 1.9 100,704-526,999 (276-1,443)
YLL, Years of life lost; YLD, years lost due to disability; DALY, Disability adjusted life 
years; §, Age and year-weighted








CaCvx ASIR/100,000 36 175 200 187
Average hourly rate (2016 $) 0.28 13.8 2.7 0.67
Cost of staging and treatment
Local disease 524 6,496 2,164 2,014
Regional disease 2,700 4,243 2,683 2,933
Metastatic disease 2,743 3,680 2,683 2,933
CaCvx, Cancer of the cervix
Table 4: Comparison of DALY in other regions and countries of 
the world
Country/Region YLD/100,000 YLL/100,000 DALY/100,000
Index study 40 229 269
Cuba 9 215 224
India 38 428 466
Bangladesh 34 520 554
North America 19 55 74
YLL, Years of life lost; YLD, years lost due to disability; DALY, Disability adjusted life years
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The estimates in this study are also more likely to be out of 
pocket expenditures, reflecting deficiencies of the national 
health insurance scheme (NHIS). At present, the scheme 
covers for only 15 cumulative days of admissions per year.[21] 
These may not sufficiently cater for patients, especially 
those with advanced disease, who may have longer spells 
of admission. In addition to this, not only are antineoplastic 
and immunosuppressive therapeutic agents on the national 
essential medicines list rudimentary, they are not covered by 
NHIS and thus not prescribed.[22,23]
Radiotherapy, the mainstay of treatment for advanced cervical 
cancer, is virtually non-existent in the country, especially 
when time spent waiting for commencement of this service 
is considered an indicator of quality of care and patient 
outcome.[24] Adewuyi and colleagues[25] reported that the 
population served by each of the 5 megavoltage machines 
in the country ranges from 20 to 40 million people per 
machine. This results in long waiting times with attendant 
poor outcome as well as significant productivity losses. 
While Nascimento and Silva[26] in Brazil report a median 
of 41 days to commencement of radiotherapy, Anakwenze 
et al.[27] in Ibadan report a median waiting time of 12.2 months 
(range: 1–44.7 months). As with chemotherapy, this service 
is also not covered by the NHIS, further worsening the cost 
burden borne by patients.
The enormous burden of cervical cancer borne by affected 
women is further exemplified by the high estimated DALY 
of 269 years per 100,000 women in our study; though 
comparable to that for Cuba, and lower than those for 
Bangladesh and India [Table 4], these figures reflect not only 
high rate of cervical cancer but also a poorer outcome when 
compared with DALY of 74 years per 100,000 women in north 
America afflicted with cervical cancer.[28,29]
The estimated 1.1 YLD reflects findings by Musa et al.[7] in 
northern Nigeria that mean time to death for advanced 
disease was 6.9 ± 7.0 months versus 23.7 ± 12.7 months for 
early disease. Thus, out of a possible 2 years, 1.1 of these are 
lived with the burden of the disease. These disability burden 
have been described by the WHO to include departures 
from good or ideal health in any of the important domains 
of health. These include mobility, self-care, participation in 
usual activities, pain and discomfort, anxiety and depression, 
and cognitive impairment.[30] However, the more alarming 
statistic is the high estimated 229 years/100,000 value of 
YLL in our study. Our data, though echoes those from other 
low-income countries [Table 4], is in stark contrast to the 
55 years/100,000 women reported for north America. This 
further highlights the mortality burden associated with the 
disease in our region of the world.
The index study shows that the cost per potential DALY 
averted ranges from ₦6,834 to ₦526,999 ($19 to $1,443) per 
woman between the ages of 35 and 75 years. The WHO has 
estimated that in 10 years (2014–2024) there is potential 
of saving $896 per DALY averted using HPV vaccination and 
$413 for a one-time visual inspection with acetic acid (VIA) 
screening in low-to-middle income countries like Nigeria.[31] 
This is supported by our estimates which show that the 
overall cost of screening, using VIA, Papaniculaou smear, 
and HPV DNA testing would be $7.7, $13.2, and $64.7, 
respectively. For a female in northern Nigeria who commences 
Pap smear screening from the age of 20 (in 2016) and screens 
5-yearly on three occasions, the cost per DALY averted would 
range from $0.94 to $44.5 [Table 5]; ₦ inflation rate of 15% and 
$ rate of 3%. This is 16 to 902 times cheaper than cost/DALY 
saved on treatment of established disease, thus making it 
cheaper to screen than treat (P value <0.00001).
This study concludes that, though burden of illness borne by 
women with cervical cancer in northern Nigeria is similar to 
that borne by women in other developing countries, it is still 
too high, and the only panacea to this is institution of early 
screening programs and immunization. In addition, concerted 
effort is needed to ensure extension of health insurance 
coverage for cancer therapy and increase in availability of 
radiotherapy service for reducing waiting times of treatment.
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